Alternative Investment Funds
United States
12 September 2024
Dechert LLP’s patent litigation team focuses on Hatch-Waxman and BPCIA litigation, and can take on cases in district courts, the ITC and the PTAB. The team is co-chaired by Katherine Helm in New York and Martin J Black in Pennsylvania. Helm is a first-chair counsel who is sought after by innovative pharmaceutical and biotechnology companies. Black is a seasoned trial lawyer capable of representing both plaintiffs and defendants. Nisha Patel Gupta, in Los Angeles, also comes recommended and stands out for her deep tech experience, which spans telecoms, computer architecture, semiconductors and medical devices.
Legal 500 Editorial commentary
Key clients
- Biogen
- DivX
- Eli Lilly & Company
- Endo Pharmaceuticals
- Genzyme
- GlaxoSmithKline
- Merck Sharp & Dohme
- Microsoft Corporation
- Sanofi
- Tekni-Plex
Work highlights
Represented Genzyme Corporation, a fully owned subsidiary of Sanofi SA, in multiple patent infringement actions in the District of Delaware and at the PTAB, related to Novartis’ manufacture, sale and use of ZOLGENSMA® (onasemnogene abeparvovec-xioi), a blockbuster gene therapy medication used to treat spinal muscular atrophy, a fatal wasting muscle disease in small children.
Representing Eli Lilly & Co. and subsidiary Point Biopharma Global in a patent dispute with Endocyte/Novartis over a billion-dollar cancer radiotherapy treatment for late-stage prostate cancer patients in a patent infringement action, with first impression issues of compassionate use programs and the safe harbor exemption to patent infringement for securing FDA approval.
Representing Biogen MA, Inc. in a patent licensing dispute involving Genentech’s “Cabilly” Patents, in which Genentech claims that Biogen owes royalty payments on sales of TYSABRI® (natalizumab) for drug product that was manufactured before but sold after the expiration of the patents.
Lawyers
Practice head
Katherine Helm; Martin J. Black
Other key lawyers
Nisha Patel Gupta